Market Cap : 2.31 B | Enterprise Value : 2.26 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. PTC Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2022 was $554.4 Mil. PTC Therapeutics's average Total Assets over the quarter that ended in Mar. 2022 was $1,868.8 Mil. Therefore, PTC Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2022 was 29.67%.
The historical data trend for PTC Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PTC Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Gross-Profit-to-Asset % falls into.
PTC Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 506.265 | / | ( (2208.278 | + | 1938.056) | / 2 ) | |
= | 506.265 | / | 2073.167 | ||||
= | 24.42 % |
PTC Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2022 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Mar. 2022 ) | / | ( (Total Assets (Q: Dec. 2021 ) | + | Total Assets (Q: Mar. 2022 )) | / count ) |
= | 554.4 | / | ( (1938.056 | + | 1799.591) | / 2 ) | |
= | 554.4 | / | 1868.8235 | ||||
= | 29.67 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of PTC Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Seekingalpha 2020-10-30
By Zacks 2022-02-22
By Zacks 2021-04-30
By Seekingalpha 2021-07-29
By Zacks 2021-10-21
By Zacks 2022-04-04
By Zacks 2021-02-25
By Zacks 2022-02-15
By Zacks 2020-08-18
By Zacks 2022-03-14
By Seekingalpha 2021-10-29
By Seekingalpha 2021-01-20
By Zacks 2021-05-27